Core Workpackages
EUnetHTA JA3 is organized into three horizontal work packages (WP1-3), and four core work packages (WP4-7). The core work packages will deliver products needed for a sustainable HTA network like quality joint assessments, evidence generation, quality management and focus on implementation of this model on national, regional and local levels. The horizontal work packages will […]
Evidence Generation – on the road to standardisation along the life-cycle of health technology
The EUnetHTA JA 2 activities addressed all relevant phases of the Life Cycle of health technology development including the pre-licensing phase (in early scientific advice (Early Dialogues) and market entry through the early assessments of the evidence in rapid REAs and additional data and evidence collection EUnetHTA Early Dialogues aim at helping pharmaceutical and MedTech companies […]
ΕΜΑ and EUnetHTA review outcome of joint 2012-2015 work plan
The European Medicines Agency (EMA) and the European network for Health Technology Assessment (EUnetHTA) published today a report on their implementation of the joint work plan covering the period between November 2012 and December 2015. The EMA-EUnetHTA collaboration aims to create synergies between regulatory evaluation and health technology assessment (HTA) along the life-cycle of a […]
EUnetHTA JA2 joint assessments – both output and process matters for successful national uptake
One of the specific objectives of JA2 was to test the capacity of national HTA bodies to produce structured core HTA information (including rapid Relative Effectiveness Assessments (REAs) together and apply it in national context. Two work packages in JA2 (WP 4 and 5) were dedicated to pilot a joint production process to produce full/comprehensive […]
EUnetHTA JA3 kick-off meeting was held in Amsterdam, Netherlands, on March 3, 2016
“Support for a more centralized European approach to evaluating new health technologies is gaining pace among the national and regional officials who perform this work in the member countries” – declared an opening line of a Health POLITICO-Pro article reporting from the EUnetHTA JA3 kick-off meeting the day after. “Support for a more centralized European […]
EUnetHTA Evidence Submission Template – a practical tool for technology developers and assessors
During the past 3 years of EUnetHTA’s operations in the framework of the Joint Action 2, an expanded suite of practical approaches and tools for HTA production has been developed and tested through a series of field-testing exercises in EUnetHTA, both in the framework of joint assessments and by individual European HTA organisations in their […]
EMA-EUnetHTA meeting summary, November 23, 2015, Copenhagen, Denmark
The last meeting of EMA-EUnetHTA in the framework of the EUnetHTA JA2 activities took place on November 23, 2015 and hosted by the Danish Health Authority in Copenhagen, Denmark. The last meeting of EMA-EUnetHTA in the framework of the EUnetHTA JA2 activities took place on November 23, 2015 and hosted by the Danish Health Authority […]
HTA Core Model® gets an update – open for use by anyone
EUnetHTA JA2 delivers an upgraded universal HTA Core Model for flexible application across health technologies. The updated HTA Core Model Licence and Guiding Principles on Use clarify conditions for its use by anyone The HTA Core Model which was first introduced by EUnetHTA in 2008 has undergone further testing and development in the past 3 […]
Call for Expression of Interest Multi HTA Early Dialogues – Pharmaceuticals
A call for Expression of Interest to participate in EUnetHTA JA3 Early Dialogues has now been published. A call for Expression of Interest to participate in EUnetHTA JA3 Early Dialogues has now been published. It is directed at healthcare product/technology developers and sponsors. Please note, the current call is restricted to pharmaceuticals, but medical devices […]
WP5-SA6 Joint “Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C” is now available
We are pleased to announce that the Joint “Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C” og WP5-SA6 is now available. This joint rapid assessment of WP5 Strand A evaluates multiple new pharmaceuticals for the treatment of Chronic Hepatitis C. Find the joint assessment here.
